News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Drugs & Diseases > Cardiology

      Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/ARVC)

      Updated: Dec 29, 2020
      • Author: Gyanendra K Sharma, MD, FACC, FASE; Chief Editor: Jose M Dizon, MD  more...
      • Print
      Overview

      Background

      Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/ARVC) is an inherited cardiomyopathy characterized by structural and functional abnormalities in the right ventricle (RV) resulting in ventricular arrhythmias. [1] It is an important cause of sudden cardiac death (SCD) in young adults, accounting for 11% of all cases and 22% of cases among athletes. [2, 3]

      ARVD was first described in 1977 and was included in the World Health Organization (WHO) classification of cardiomyopathies in 1996. [4] Since then, there have been significant advances in the understanding of its etiopathogenesis, diagnosis, and management. [5]

      Next:

      Pathophysiology

      The structural abnormalities in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/ARVC) result from the fatty infiltration and fibrosis of the RV myocardium. This leads to progressive RV dilatation and dysfunction. The left ventricle (LV) is less commonly involved, and the septum is relatively spared. [6] However, in a cohort of 200 probands, Sen-Chowdhry et al found that LV involvement may even precede the onset of significant RV dysfunction. [7] The prognosis is worse in patients with LV involvement. [8]

      The mechanisms for myocardial loss include the following:

      • Apoptosis (programmed cell death)

      • Inflammation, enhanced fibrosis, and loss of function

      • Fatty replacement of myocardium

      Previous
      Next:

      Etiology

      Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/ARVC) is an inherited disorder, as it is already present in the fetus. Familial cases account for 30%-90% of cases. [9] In other cases, it may result from an acquired etiology such as viral infection (myocarditis) or unidentified inheritance. It is also likely that patients with a genetic predisposition are more likely to develop myocarditis.

      The disease manifests more frequently in active individuals, when mechanical sheer stress can cause cell membrane damage, inflammation, and fibrosis in genetically predisposed RV.

      Genetics

      ARVD is considered a genetic disorder, as most cases are familial, and there is geographical clustering. The most common pattern of inheritance is autosomal dominance, with a variable penetrance ranging from 20%-35% of family members. [10, 11] People living in the Veneto region of Italy have a higher penetrance. The autosomal-recessive (Naxos disease) pattern of inheritance is localized to the Greek island of Naxos and is associated with palmoplantar keratosis and wooly hair. The genetic mutation occurs on chromosome 17q21, and penetrance is almost 100%. [12, 13]

      Genetic abnormalities in ARVD are located on chromosomes 1, 2, 3, 6, 7, 10, 12, and 14. There is no single unique genetic abnormality, posing a challenge in evaluation of patients and families with suspected ARVD. The responsible genes include plakoglobin (JUP), desmoplakin (DSP), plakophilin-2 (PKP2), desmoglein-2 (DSG2), desmocollin-2 (DSC2), and others. [14, 15, 16]  In some cases, mutation in the SCN5A gene may cause dysfunction in the cardiac voltage-gated sodium channel (Nav1.5), resulting in cardiomyopathy. [17]

      The Heart Rhythm Society and the European Heart Rhythm Association published a consensus statement on genetic testing for cardiomyopathies. [18]

      Previous
      Next:

      Epidemiology

      Because of the diagnostic challenge, the exact incidence and prevalence of arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/ARVC) remains unknown, as clinically silent cases may go unrecognized. [19] It is estimated that it affects 1 in 1000-5000 population and is more common in individuals of Greek and Italian origin. [20]

      In a cohort of 100 patients from the United States, the median age at presentation was 26 years, and 51% were males. The median time to diagnosis was one year from the initial presentation, and median survival in the entire cohort was 60 years. [21]

      Previous
      Next:

      Prognosis

      Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/ARVC) is an important cause of sudden cardiac death in young adults, accounting for 11% of all cases and 22% of cases among athletes.

      The prognosis is worse in patients with left ventricular (LV) involvement.

      Pregnancy is mostly well tolerated, but Hodes et al found 13% of pregnancies in women with ARVD/ARVC were complicated by ventricular arrhythmias and 5% by heart failure. [22]

      Sustained ventricular arrhythmias are more common in men, and they have significantly abnormal electrocardiograms. [23]

      Cardiac magnetic resonance imaging (CMRI) to assess tissue characteristics and a 5-year risk score model has been proposed. [24]  In a study of 140 patients with ARVC, CMRI was normal in 14 patients who did not have any major events. LV-dominant abnormalities were found in 16 patients (12%). [25] Isolated RV involvement was seen in 41% patients and biventricular involvement was seen in 37% patients. LV involvement had a worse prognosis than RV involvement alone. However, the risk score model underestimated the risk in those who had LV involvement. [25]

      Previous
      Clinical Presentation
       
       
      Media Gallery
      of 7
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate
      Editions
      English Deutsch Español Français Português
      All material on this website is protected by copyright, Copyright © 1994-2022 by WebMD LLC. This website also contains material copyrighted by 3rd parties.